BAM
MRKR icon

Belpointe Asset Management’s Marker Therapeutics MRKR Stock Holding History

Belpointe Asset Management’s Portfolio MRKR Stock Details MRKR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,100
Closed -$781 – 2279
2023
Q1 		$781 Buy
1,100
+100
+10% +$238 ﹤0.01% 3515
2022
Q4 		$2.66K Buy
+1,000
New +$3.45K ﹤0.01% 3165

Other funds holding MRKR

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return
AAM
AR Asset Management West Hollywood, California $517M AUM 18.31% 1-Year Est. Return
MAA
Matrix Asset Advisors White Plains, New York $1.23B AUM 26.4% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Belpointe Asset Management's MRKR Position: Q2 2023 in Review

Belpointe Asset Management sold out of Marker Therapeutics (MRKR) in Q2 2023, closing a stake of 1,100 shares — an estimated $781 sold.

Belpointe Asset Management first reported a position in MRKR in Q4 2022 and held it in 2 quarters. The position peaked at $2.66K in Q4 2022. 29 funds tracked by Wall St. Rank hold MRKR as of Q2 2023.

  • Belpointe Asset Management reported no remaining Marker Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Belpointe Asset Management sold 1,100 Marker Therapeutics shares in Q2 2023, an estimated $781.
  • Belpointe Asset Management first reported a position in Marker Therapeutics in Q4 2022 and held it in 2 quarters.
  • Belpointe Asset Management's Marker Therapeutics position peaked at $2.66K in Q4 2022.
  • 29 funds tracked by Wall St. Rank held Marker Therapeutics as of Q2 2023.

Based on Belpointe Asset Management's 13F filing for Q2 2023, filed 15 Aug 2023.